Breaking News Instant updates and real-time market news.

VMC

Vulcan Materials

$167.86 /

+2.835 (+1.72%)

16:37
05/13/22
05/13
16:37
05/13/22
16:37

Vulcan Materials provides update on Mexican SAC TUN operations

Vulcan Materials provided an update with respect to its Mexican SAC TUN operations. Vulcan Materials confirmed that the Mexican government has suspended the three-year customs permit granted in March 2022 to the Mexican subsidiary of the company and has begun a proceeding that could result in the revocation of that permit. A decision to maintain or revoke the permit will be made within weeks. This routinely renewed permit had been recently granted for customs purposes at the port terminal within our property. The port terminal is operated by the company pursuant to a concession that is valid through 2037. The permit enables Vulcan's subsidiary to export its production to the United States; however, absent the customs permit no export or import operations of any kind may be conducted by any entity at the port terminal. As with the arbitrary shutdown orders to immediately cease underwater quarrying and extraction operations received on May 5, Vulcan strongly believes that this latest action by Mexico is arbitrary and illegal. These adverse measures have the effect of shutting down the operations of SAC TUN in Quintana Roo, Mexico. Vulcan has sought injunctive relief in Mexico that, if granted and complied with, would enable the company to resume normal operations including the extraction, processing and export of materials. Should the company be unable to fully operate in Mexico for the balance of 2022, the potential EBITDA impact would range from $80M-$100M, which would approximate 5% of Vulcan's Adjusted EBITDA guidance of $1.72B-$1.82B for 2022. The company intends to vigorously pursue all lawful avenues available to it in order to protect its rights, under both Mexican and international law, and resume normal operations as soon as permitted. The company has quarried limestone legally in Mexico - on land that it owns - for over 30 years. Vulcan has the right to maintain full ownership of its properties, owns the limestone reserves in the same, and complies and has always complied with Mexican law, including the laws and permitting regulating our operations from which we service our customers in the United States, Mexico and the Caribbean basin. Since late 2018, Vulcan Materials has been engaged in a NAFTA arbitration with Mexico over Mexico's repudiation of an agreement to unlock a portion of Vulcan's aggregates reserves in Mexico and the arbitrary shutdown of a different portion of the company's quarrying operations there. A hearing took place in July 2021, and a decision is expected in the second half of 2022. This decision may be delayed if the Tribunal accepts the company's recent request to hear the new NAFTA violations related to Mexico's latest measures. Vulcan has continued to engage with government officials to pursue an amicable resolution of the dispute while awaiting the final resolution from the NAFTA tribunal.

  • 13

    May

OTHER BREAKING NEWS FROM THE FLY

Initiation
Synopsys assumed with an Overweight at Atlantic Equities » 06:24
12/01/22
12/01
06:24
12/01/22
06:24
SNPS

Synopsys

$339.57 /

+16.07 (+4.97%)

Atlantic Equities analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SNPS Synopsys
$339.57 /

+16.07 (+4.97%)

SNPS Synopsys
$339.57 /

+16.07 (+4.97%)

11/22/22 Wells Fargo
Synopsys price target lowered to $400 from $425 at Wells Fargo
11/16/22 Edward Jones
Synopsys initiated with a Hold at Edward Jones
09/29/22 Deutsche Bank
Synopsys initiated with a Buy at Deutsche Bank
09/07/22 Stifel
Stifel starts Cadence Design at Hold, prefers Synopsys on valuation basis
SNPS Synopsys
$339.57 /

+16.07 (+4.97%)

SNPS Synopsys
$339.57 /

+16.07 (+4.97%)

SNPS Synopsys
$339.57 /

+16.07 (+4.97%)

Recommendations
Snowflake price target lowered to $180 from $197 at Raymond James » 06:24
12/01/22
12/01
06:24
12/01/22
06:24
SNOW

Snowflake

$142.87 /

+6.255 (+4.58%)

Raymond James analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SNOW Snowflake
$142.87 /

+6.255 (+4.58%)

SNOW Snowflake
$142.87 /

+6.255 (+4.58%)

06:22 Today UBS
Snowflake price target lowered to $140 from $175 at UBS
11/22/22 Baird
Snowflake price target lowered to $185 from $215 at Baird
11/18/22 Barclays
Snowflake price target lowered to $200 from $207 at Barclays
11/08/22 Truist
Snowflake price target lowered to $200 from $225 at Truist
SNOW Snowflake
$142.87 /

+6.255 (+4.58%)

SNOW Snowflake
$142.87 /

+6.255 (+4.58%)

SNOW Snowflake
$142.87 /

+6.255 (+4.58%)

Downgrade
Liberty Global downgraded to Neutral from Overweight at JPMorgan » 06:24
12/01/22
12/01
06:24
12/01/22
06:24
LBTYA

Liberty Global

$20.07 /

+0.325 (+1.65%)

JPMorgan analyst Akhil…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LBTYA Liberty Global
$20.07 /

+0.325 (+1.65%)

LBTYA Liberty Global
$20.07 /

+0.325 (+1.65%)

10/17/22 Deutsche Bank
Liberty Global price target lowered to $29.50 from $32 at Deutsche Bank
10/14/22 Citi
Liberty Global initiated with a Neutral at Citi
09/30/22 Barclays
Liberty Global price target lowered to $22 from $25 at Barclays
09/16/22 Barclays
Liberty Global price target lowered to EUR 25 from EUR 28 at Barclays
LBTYA Liberty Global
$20.07 /

+0.325 (+1.65%)

LBTYA Liberty Global
$20.07 /

+0.325 (+1.65%)

LBTYA Liberty Global
$20.07 /

+0.325 (+1.65%)

Upgrade
Vantage Towers upgraded to Neutral from Underweight at JPMorgan » 06:23
12/01/22
12/01
06:23
12/01/22
06:23
VTWRF

Vantage Towers

$33.80 /

+ (+0.00%)

JPMorgan analyst Akhil…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VTWRF Vantage Towers
$33.80 /

+ (+0.00%)

11/21/22 Jefferies
Vantage Towers downgraded to Hold from Buy at Jefferies
10/05/22 JPMorgan
Vantage Towers price target lowered to EUR 26.50 from EUR 27 at JPMorgan
09/06/22 Citi
Vantage Towers upgraded to Buy from Neutral at Citi
09/02/22 Credit Suisse
Vantage Towers initiated with a Neutral at Credit Suisse
Recommendations
Snowflake price target lowered to $140 from $175 at UBS » 06:22
12/01/22
12/01
06:22
12/01/22
06:22
SNOW

Snowflake

/

+

UBS analyst Karl…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SNOW Snowflake
/

+

SNOW Snowflake
/

+

11/22/22 Baird
Snowflake price target lowered to $185 from $215 at Baird
11/18/22 Barclays
Snowflake price target lowered to $200 from $207 at Barclays
11/08/22 Truist
Snowflake price target lowered to $200 from $225 at Truist
11/08/22 Mizuho
Snowflake price target lowered to $185 from $225 at Mizuho
SNOW Snowflake
/

+

SNOW Snowflake
/

+

SNOW Snowflake
/

+

Upgrade
Elisa upgraded to Overweight from Neutral at JPMorgan » 06:22
12/01/22
12/01
06:22
12/01/22
06:22
ELMUF

Elisa

$55.20 /

+ (+0.00%)

JPMorgan analyst Akhil…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ELMUF Elisa
$55.20 /

+ (+0.00%)

10/20/22 JPMorgan
Elisa price target lowered to EUR 63 from EUR 64 at JPMorgan
10/18/22 Credit Suisse
Elisa upgraded to Outperform from Neutral at Credit Suisse
10/05/22 UBS
Elisa price target lowered to EUR 50.80 from EUR 54.60 at UBS
09/30/22 DNB Markets
Elisa downgraded to Sell from Hold at DNB Markets
Downgrade
Primary Health Properties downgraded to Underweight from Overweight at Barclays » 06:19
12/01/22
12/01
06:19
12/01/22
06:19
PHPRF

Primary Health Properties

$1.23 /

+ (+0.00%)

Barclays analyst Kanad…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PHPRF Primary Health Properties
$1.23 /

+ (+0.00%)

07/05/22 Barclays
Primary Health Properties price target lowered to 140 GBp from 160 GBp at Barclays
04/28/22 Stifel
Primary Health Properties downgraded to Hold from Buy at Stifel
Initiation
Brunello Cucinelli initiated with a Buy at UBS » 06:18
12/01/22
12/01
06:18
12/01/22
06:18
BCUCY

Brunello Cucinelli

$32.31 /

+ (+0.00%)

UBS analyst Chris Huang…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BCUCY Brunello Cucinelli
$32.31 /

+ (+0.00%)

10/20/22 Deutsche Bank
Brunello Cucinelli price target raised to EUR 48 from EUR 46 at Deutsche Bank
10/20/22 Societe Generale
Brunello Cucinelli price target raised to EUR 37 from EUR 34 at Societe Generale
10/20/22 Jefferies
Brunello Cucinelli upgraded to Buy from Hold at Jefferies
08/02/22 Deutsche Bank
Brunello Cucinelli price target raised to EUR 46 from EUR 34 at Deutsche Bank
Downgrade
Leslie's downgraded to Hold from Buy at Stifel » 06:16
12/01/22
12/01
06:16
12/01/22
06:16
LESL

Leslie's

$14.61 /

-0.475 (-3.15%)

Stifel analyst W. Andrew…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LESL Leslie's
$14.61 /

-0.475 (-3.15%)

LESL Leslie's
$14.61 /

-0.475 (-3.15%)

11/28/22 Stifel
Leslie's price target lowered to $17 from $20 at Stifel
11/15/22 Baird
Leslie's downgraded to Neutral from Outperform at Baird
10/03/22 MKM Partners
MKM Partners starts Leslie's at Neutral, sees higher costs impact profitability
10/03/22 MKM Partners
Leslie's initiated with a Neutral at MKM Partners
LESL Leslie's
$14.61 /

-0.475 (-3.15%)

  • 15
    Dec
LESL Leslie's
$14.61 /

-0.475 (-3.15%)

LESL Leslie's
$14.61 /

-0.475 (-3.15%)

Upgrade
Lennox upgraded to Overweight from Equal Weight at Wells Fargo » 06:15
12/01/22
12/01
06:15
12/01/22
06:15
LII

Lennox

$259.94 /

-1 (-0.38%)

Wells Fargo analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LII Lennox
$259.94 /

-1 (-0.38%)

LII Lennox
$259.94 /

-1 (-0.38%)

11/01/22 JPMorgan
Lennox upgraded to Neutral from Underweight at JPMorgan
10/31/22 Wells Fargo
Lennox price target lowered to $238 from $249 at Wells Fargo
10/13/22 Deutsche Bank
Lennox price target lowered to $287 from $302 at Deutsche Bank
10/13/22 Deutsche Bank
Lennox named short-term buy idea at Deutsche Bank
LII Lennox
$259.94 /

-1 (-0.38%)

LII Lennox
$259.94 /

-1 (-0.38%)

Initiation
GoodRx initiated with a Buy at Citi » 06:14
12/01/22
12/01
06:14
12/01/22
06:14
GDRX

GoodRx

$4.35 /

-0.09 (-2.03%)

Citi analyst Daniel…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GDRX GoodRx
$4.35 /

-0.09 (-2.03%)

GDRX GoodRx
$4.35 /

-0.09 (-2.03%)

11/10/22 Deutsche Bank
GoodRx price target lowered to $7 from $9 at Deutsche Bank
11/04/22 JPMorgan
GoodRx upgraded to Neutral from Underweight at JPMorgan
10/11/22 Barclays
GoodRx price target lowered to $9 from $13 at Barclays
09/15/22 KeyBanc
GoodRx initiated with a Sector Weight at KeyBanc
GDRX GoodRx
$4.35 /

-0.09 (-2.03%)

GDRX GoodRx
$4.35 /

-0.09 (-2.03%)

GDRX GoodRx
$4.35 /

-0.09 (-2.03%)

Recommendations
Salesforce price target lowered to $185 from $200 at Oppenheimer » 06:13
12/01/22
12/01
06:13
12/01/22
06:13
CRM

Salesforce

$159.94 /

+8.22 (+5.42%)

Oppenheimer analyst Brian…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CRM Salesforce
$159.94 /

+8.22 (+5.42%)

CRM Salesforce
$159.94 /

+8.22 (+5.42%)

11/29/22 KeyBanc
Salesforce price target lowered to $200 from $210 at KeyBanc
11/29/22 Baird
Salesforce price target lowered to $210 from $230 at Baird
11/28/22 Evercore ISI
Salesforce price target lowered to $200 from $225 at Evercore ISI
11/28/22 Stifel
Salesforce price target lowered to $185 from $200 at Stifel
CRM Salesforce
$159.94 /

+8.22 (+5.42%)

CRM Salesforce
$159.94 /

+8.22 (+5.42%)

CRM Salesforce
$159.94 /

+8.22 (+5.42%)

CRM Salesforce
$159.94 /

+8.22 (+5.42%)

Recommendations
Correction: Hub Group not downgraded today at Wolfe Research  06:13
12/01/22
12/01
06:13
12/01/22
06:13
HUBG

Hub Group

$84.14 /

+1.29 (+1.56%)

 
ShowHide Related Items >><<
HUBG Hub Group
$84.14 /

+1.29 (+1.56%)

HUBG Hub Group
$84.14 /

+1.29 (+1.56%)

11/17/22 Wolfe Research
Wolfe reshuffles ratings in freight with five downgrades and one upgrade
11/17/22 Wolfe Research
Hub Group downgraded to Peer Perform from Outperform at Wolfe Research
10/11/22 Barclays
Hub Group price target lowered to $75 from $82 at Barclays
08/10/22 Susquehanna
Hub Group price target raised to $117 from $115 at Susquehanna
HUBG Hub Group
$84.14 /

+1.29 (+1.56%)

Syndicate
Abeona Therapeutics files to sell 15.2M shares of common stock for holders  06:12
12/01/22
12/01
06:12
12/01/22
06:12
ABEO

Abeona Therapeutics

$3.77 /

-0.06 (-1.57%)

 
ShowHide Related Items >><<
ABEO Abeona Therapeutics
$3.77 /

-0.06 (-1.57%)

ABEO Abeona Therapeutics
$3.77 /

-0.06 (-1.57%)

11/08/22 Cantor Fitzgerald
Abeona Therapeutics price target raised to $40 from $22 at Cantor Fitzgerald
11/04/22 Alliance Global Partners
Abeona's EB-101 results 'dramatically positive,' says Alliance Global Partners
09/15/22 Alliance Global Partners
Abeona Therapeutics initiated with a Buy at Alliance Global Partners
08/11/22 Cantor Fitzgerald
Abeona Therapeutics price target raised to $22 from $15 at Cantor Fitzgerald
ABEO Abeona Therapeutics
$3.77 /

-0.06 (-1.57%)

  • 17
    Dec
Periodicals
Amazon CEO Jassy doesn't regret hiring spree as layoffs begin, WSJ reports » 06:12
12/01/22
12/01
06:12
12/01/22
06:12
AMZN

Amazon.com

$96.50 /

+4.1 (+4.44%)

Amazon CEO Andy Jassy…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

11/30/22 JMP Securities
JMP Securities encouraged by Amazon.com's focus on innovation
11/29/22 UBS
Affirm initiated with a Neutral at UBS
11/22/22 Piper Sandler
Amazon.com price target lowered to $119 from $125 at Piper Sandler
11/21/22 JPMorgan
JPMorgan more cautious on online holiday sales, Amazon still top idea
AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

Periodicals
CEO Jassy says Amazon has no plans to remove anti-Semitic film, NY Times report » 06:12
12/01/22
12/01
06:12
12/01/22
06:12
AMZN

Amazon.com

$96.50 /

+4.1 (+4.44%)

Amazon CEO Andy Jassy…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

11/30/22 JMP Securities
JMP Securities encouraged by Amazon.com's focus on innovation
11/29/22 UBS
Affirm initiated with a Neutral at UBS
11/22/22 Piper Sandler
Amazon.com price target lowered to $119 from $125 at Piper Sandler
11/21/22 JPMorgan
JPMorgan more cautious on online holiday sales, Amazon still top idea
AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

AMZN Amazon.com
$96.50 /

+4.1 (+4.44%)

Syndicate
Iveric bio 13.35M share Spot Secondary priced at $22.50 » 06:12
12/01/22
12/01
06:12
12/01/22
06:12
ISEE

Iveric bio

$23.60 /

+0.77 (+3.37%)

The deal size was…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ISEE Iveric bio
$23.60 /

+0.77 (+3.37%)

ISEE Iveric bio
$23.60 /

+0.77 (+3.37%)

11/10/22 Jefferies
Apellis downgraded to Hold at Jefferies after doctor survey
11/10/22 Jefferies
Iveric bio downgraded to Hold at Jefferies after doctor survey
11/10/22 Jefferies
Iveric bio downgraded to Hold from Buy at Jefferies
10/17/22 B. Riley
Iveric bio upgraded to Neutral at B. Riley after competitor in GA 'disappoints'
ISEE Iveric bio
$23.60 /

+0.77 (+3.37%)

  • 01
    Dec
ISEE Iveric bio
$23.60 /

+0.77 (+3.37%)

ISEE Iveric bio
$23.60 /

+0.77 (+3.37%)

Initiation
ADT Inc. resumed with a Buy at Citi » 06:11
12/01/22
12/01
06:11
12/01/22
06:11
ADT

ADT Inc.

$9.34 /

+0.135 (+1.47%)

Citi analyst Peter…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ADT ADT Inc.
$9.34 /

+0.135 (+1.47%)

ADT ADT Inc.
$9.34 /

+0.135 (+1.47%)

10/31/22 Morgan Stanley
ADT Inc. resumed with an Equal Weight at Morgan Stanley
01/06/22 RBC Capital
ADT Inc. downgraded to Sector Perform at RBC Capital on free cash flow headwinds
01/06/22 RBC Capital
ADT Inc. downgraded to Sector Perform from Outperform at RBC Capital
01/05/22 Citi
ADT Inc. resumed with a Buy at Citi
ADT ADT Inc.
$9.34 /

+0.135 (+1.47%)

ADT ADT Inc.
$9.34 /

+0.135 (+1.47%)

ADT ADT Inc.
$9.34 /

+0.135 (+1.47%)

ADT ADT Inc.
$9.34 /

+0.135 (+1.47%)

Hot Stocks
Bank of Montreal raises quarterly dividend 3% to C$1.43 per share » 06:11
12/01/22
12/01
06:11
12/01/22
06:11
BMO

Bank of Montreal

$97.83 /

+1.73 (+1.80%)

The dividend on the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BMO Bank of Montreal
$97.83 /

+1.73 (+1.80%)

BMO Bank of Montreal
$97.83 /

+1.73 (+1.80%)

11/22/22 Scotiabank
Bank of Montreal price target lowered to C$156 from C$159 at Scotiabank
11/18/22 National Bank
Bank of Montreal price target lowered to C$147 from C$151 at National Bank
09/01/22 Desjardins
Bank of Montreal price target lowered to C$150 from C$153 at Desjardins
09/01/22 Canaccord
Bank of Montreal price target lowered to C$150.50 from C$152.50 at Canaccord
BMO Bank of Montreal
$97.83 /

+1.73 (+1.80%)

BMO Bank of Montreal
$97.83 /

+1.73 (+1.80%)

Recommendations
Okta price target lowered to $85 from $95 at Oppenheimer » 06:11
12/01/22
12/01
06:11
12/01/22
06:11
OKTA

Okta

$53.31 /

+2.06 (+4.02%)

Oppenheimer analyst Ittai…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
OKTA Okta
$53.31 /

+2.06 (+4.02%)

OKTA Okta
$53.31 /

+2.06 (+4.02%)

11/29/22 Jefferies
Okta risk/reward attractive amid low expectations, says Jefferies
11/22/22 Piper Sandler
Okta price target lowered to $80 from $125 at Piper Sandler
11/14/22 Canaccord
Okta price target lowered to $70 from $85 at Canaccord
11/14/22 JMP Securities
Okta price target lowered to $105 from $145 at JMP Securities
OKTA Okta
$53.31 /

+2.06 (+4.02%)

OKTA Okta
$53.31 /

+2.06 (+4.02%)

OKTA Okta
$53.31 /

+2.06 (+4.02%)

OKTA Okta
$53.31 /

+2.06 (+4.02%)

Earnings
Bank of Montreal reports Q4 adjusted EPS C$3.04 vs. C$3.33 a year ago » 06:10
12/01/22
12/01
06:10
12/01/22
06:10
BMO

Bank of Montreal

$97.83 /

+1.73 (+1.80%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BMO Bank of Montreal
$97.83 /

+1.73 (+1.80%)

BMO Bank of Montreal
$97.83 /

+1.73 (+1.80%)

11/22/22 Scotiabank
Bank of Montreal price target lowered to C$156 from C$159 at Scotiabank
11/18/22 National Bank
Bank of Montreal price target lowered to C$147 from C$151 at National Bank
09/01/22 Desjardins
Bank of Montreal price target lowered to C$150 from C$153 at Desjardins
09/01/22 Canaccord
Bank of Montreal price target lowered to C$150.50 from C$152.50 at Canaccord
BMO Bank of Montreal
$97.83 /

+1.73 (+1.80%)

BMO Bank of Montreal
$97.83 /

+1.73 (+1.80%)

Syndicate
Intellia Therapeutics 6.55M share Spot Secondary priced at $45.80 » 06:10
12/01/22
12/01
06:10
12/01/22
06:10
NTLA

Intellia Therapeutics

$51.41 /

+3.44 (+7.17%)

The deal size was…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

11/14/22 Chardan
Intellia Therapeutics price target raised to $129 from $121 at Chardan
11/03/22 Chardan
Intellia Therapeutics price target lowered to $121 from $146 at Chardan
10/31/22 EF Hutton
Intellia Therapeutics initiated with a Buy at EF Hutton
10/11/22 Morgan Stanley
Intellia Therapeutics initiated with an Overweight at Morgan Stanley
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

  • 01
    Dec
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

Recommendations
Elastic price target lowered to $90 from $110 at Oppenheimer » 06:10
12/01/22
12/01
06:10
12/01/22
06:10
ESTC

Elastic

$61.16 /

+2.16 (+3.66%)

Oppenheimer analyst Ittai…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ESTC Elastic
$61.16 /

+2.16 (+3.66%)

ESTC Elastic
$61.16 /

+2.16 (+3.66%)

11/18/22 Barclays
Elastic price target lowered to $80 from $85 at Barclays
10/26/22 Truist
Elastic price target lowered to $95 from $105 at Truist
10/19/22 Baird
Elastic assumed with an Outperform at Baird
10/18/22 Barclays
Elastic price target lowered to $85 from $105 at Barclays
ESTC Elastic
$61.16 /

+2.16 (+3.66%)

ESTC Elastic
$61.16 /

+2.16 (+3.66%)

ESTC Elastic
$61.16 /

+2.16 (+3.66%)

Hot Stocks
Wallbox appoints new Chief Communications and Public Affairs Officer, CMO » 06:10
12/01/22
12/01
06:10
12/01/22
06:10
WBX

Wallbox

$5.59 /

+0.24 (+4.49%)

Wallbox announced two…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
WBX Wallbox
$5.59 /

+0.24 (+4.49%)

WBX Wallbox
$5.59 /

+0.24 (+4.49%)

11/22/22 Northland
Wallbox initiated with an Outperform at Northland
11/10/22 Canaccord
Wallbox price target lowered to $13 from $14 at Canaccord
11/10/22 Baird
Wallbox price target lowered to $14 from $20 at Baird
09/07/22 Credit Suisse
Wallbox initiated with an Outperform at Credit Suisse
WBX Wallbox
$5.59 /

+0.24 (+4.49%)

Recommendations
Portage Biotech price target lowered to $21 from $22 at H.C. Wainwright » 06:09
12/01/22
12/01
06:09
12/01/22
06:09
PRTG

Portage Biotech

$5.75 /

-0.15 (-2.54%)

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PRTG Portage Biotech
$5.75 /

-0.15 (-2.54%)

PRTG Portage Biotech
$5.75 /

-0.15 (-2.54%)

11/30/22 Cantor Fitzgerald
Portage Biotech price target lowered to $18 from $26 at Cantor Fitzgerald
11/30/22 Oppenheimer
Portage Biotech price target lowered to $18 from $26 at Oppenheimer
09/20/22 H.C. Wainwright
Portage Biotech price target lowered to $22 from $32 at H.C. Wainwright
07/15/22 Oppenheimer
Portage Biotech assumed with an Outperform at Oppenheimer
PRTG Portage Biotech
$5.75 /

-0.15 (-2.54%)

PRTG Portage Biotech
$5.75 /

-0.15 (-2.54%)

PRTG Portage Biotech
$5.75 /

-0.15 (-2.54%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.